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ABSTRACT
The Development of Novel Apurinic/Aprymidinic Endonuclease/Redox-factor 1 Inhibitors for
the Treatment of Human Melanoma
by Bella (Banafsheh) Sharifi
Apurinic/apyrimidinic DNA repair endonuclease-1 (APE1), first recognized as an important DNA
excision repair enzyme, is also known as Redox Factor-1 (Ref-1) involved in the activation of
many nuclear transcription factors in both redox-dependent and independent manner. It has been
well-documented that the overexpression of APE/Ref-1 contributes to the development of chemoresistance and is associated with tumor progression in many human malignancies [1]. Our previous
study in melanoma demonstrated that the development of novel inhibitors targeting the redox
regulation domain of APE/Ref-1 is a promising strategy for melanoma treatment. To date, limited
successes have been reported in developing novel APE/Ref-1 inhibitors for cancer treatment.
Utilizing a structure-based approach, our study identified and characterized small molecular
inhibitors of APE/Ref-1. First, N-terminally truncated APE/Ref-1 protein lacking the first 40
amino acid residues (∆40APE-1wt) was cloned into the pGEX-6P1 vector to express the GST∆40APE-1wt protein. After cleavage of GST-tag, the concentrated ∆40APE-1wt protein was
subjected to protein crystallization study. We have successfully diffracted ∆40APE-1wt crystals
and collected data with a resolution of 1.57Å. The crystal structure was further determined by
molecular replacement in Molrep using the already available human APE-1 structure (PDB:
5CFG). For the first time, we observed the dimerization of APE/Ref-1 protein formed under
oxidative conditions, which may contribute to the redox regulation of APE/Ref-1. Such structural
transformation of APE/Ref-1 protein under distinct redox conditions may pave the way for future
drug development and optimization. The binding affinity of the candidate compounds with
∆40APE-1wt protein was also determined using Surface Plasmon Resonance (SPR), and the Ki
V

values were analyzed. One of the potent inhibitors developed by our group by structure-based
approach, exhibited promising anti-melanoma activities both in vitro and in vivo. Future studies
on the structure-activity association are warranted.
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1 Chapter 1
1.1

Introduction

While the incidence of many of the most commonly diagnosed cancers in the United States (e.g.,
breast, colorectal and prostate cancer) have been declining for more than a decade, malignant
melanoma remains one of the few cancer types in which the incidence continues to rise, raising
substantial public health concerns [2]. Highly effective therapy is primarily limited to surgery,
which occurs only when the diagnosis is achieved at the early stages of the disease; traditional
chemotherapy is not highly effective in more advanced stages of melanoma with only 24.8% of
patients with distant metastasis surviving over five years [3]. In recent years, there have been
dramatic developments in the treatment of advanced cutaneous melanoma (CM) using
revolutionary immunotherapy [4]. Although these powerful checkpoint inhibitors yield remarkable
and durable responses in melanoma patients, they are mainly indicated for patients with advanced
melanoma and disease progression following other treatments [5]. Furthermore, although such
incredible progress in the treatment of melanoma has been made, the world-wide melanoma
epidemic has not been slowed down. This disease continues to be an immense public health
challenge, especially in the United States. Therefore, more novel and effective strategies blocking
melanoma genesis and disease progression to the advanced stage are highly desired [6].
The aberrant signal pathways or mutant genes observed in cancer cells may be their “Achilles
Heel,” which can be utilized as druggable targets for developing novel targeted therapy [7]. Driven
by this strategy, our research is focused on identifying effective novel targets and approaches for
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melanoma prevention and therapy, primarily through the extensive mechanistic studies of
abnormal redox signal pathways identified in melanoma during disease progression.
APE/Ref-1, first recognized as a DNA endonuclease base excision repair (BER) enzyme, which
plays an important role in redox signaling pathways via reduction of oxidized cysteine residues of
many nuclear transcription factors (TFs), such as Nrf-2, NF-κb and AP-1, resulting in
transcriptional activation of genes associated with cancer proliferation and progression [8]. Of
note, abnormal expression of APE/Ref-1 is reported in many human malignancies, including
melanoma. Our previous studies have shown that APE/Ref-1 plays an essential role in melanoma
progression and the development of drug resistance. Targeting APE/Ref-1 using small molecular
inhibitors is shown as a potent and effective strategy for melanoma therapy. A novel APE/Ref-1
inhibitor, APX3330 (known as E3330), exhibits promising pre-clinical anti-tumor activities and is
currently studied in a clinical trial [8].

1.2

APE/Ref-1 function and role in melanoma development/drug resistance

Throughout the life cycle, organisms and cells undergo constant DNA endogenous and exogenous
damages caused by respiration, replication, ultraviolet (UV) or ionizing radiation (IR). Depending
on the severity of these DNA damages, cells can either arrest to overcome the damage or undergo
apoptosis [9]. Human APE/Ref-1 consists of 318 amino acids, with a molecular weight of 36.5
kDa [10]. Further studies have shown that APE/Ref-1 contains three distinct functional domains.
The first 25-33 N-terminal unstable structured amino acid sequences are responsible for nuclear
localization signaling. Deletion study of the first 40 amino acids responsible for nuclear
localization and loss of function showed that the truncated APE/Ref-1 fails to translocate to the
nucleus. This domain is also called nuclear localization signal domain [11]. The second N-terminal
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region amino acids are responsible for redox activity. This region is followed by the third domain
at the C-terminal region, which is responsible for DNA repair activity. Studies showed that
APE/Ref-1, functioning as an important endonuclease, effectively repairs oxidative DNA damage
via the base excision repair pathway (BER) [11].
It has been well studied that APE/Ref-1-mediated signaling plays an important role in cancer
development and progression. The expression of APE/Ref-1 is known to be highly sensitive to
redox-status alterations. Our previous studies consistently demonstrated abnormally elevated
nuclear APE/Ref-1 in human melanoma cells compared with normal melanocytes, which is
associated with drug resistance and proliferation [12]. Cells exposure to elevated levels of ROS
can regulate APE/Ref-1 activity and expression on both transcriptional and posttranscriptional
levels [13]. Since melanoma cells exhibit abnormal intracellular redox status, the induction of
APE/Ref-1 observed in tumor biopsies may be an adaptive response to the prolonged exposure of
oxidative stress, which contributed to cell proliferation and disease progression [12].
Studies done in other human malignancies such as pancreatic and ovarian cancers have also
demonstrated up-regulation of APE/Ref-1 secondary to oxidative DNA damage [11]. As a result,
overexpression of APE/Ref-1 is associated with increased cell survival from chemotherapy and
DNA-interactive drugs [11]. Taken together, APE/Ref-1 might be a promising druggable target to
improve the outcomes of melanoma therapy. The critical role of APE/Ref-1 in promotion,
progression, and drug resistance in melanoma and other types of tumors, states its target potency
for development of new cancer therapeutic and preventive strategies [12]. Thus, in recent years,
further efforts have been directed to identify, design, and develop small molecule inhibitors of
APE/Ref-1 to improve cancer treatments [10].

3

As such, the ultimate goal of our study is to develop novel and potent inhibitors, which can
selectively block the redox activity of APE/Ref-1.

1.3

APE/Ref-1-mediated redox regulation of nuclear transcription factors

Epidemiology studies showed that certain risk factors or environmental exposure, such as indoor
tanning, atypical mole, fair skin type as well as excessive UV exposure at a young age are
associated with increased risk of developing melanoma [10]. Melanin is the major pigment found
in the hair, the epidermis, and the brain as well as other highly nerve-active areas such as retina
and middle ear. It is a unique product of melanocyte cells and is responsible for skin protection
from photochemical stress [12]. Melanin plays as a disposable buffer as it neutralizes upregulation
of reactive oxygen species (ROS) generated by ultraviolet radiation. The mechanism by which
melanin consumes oxygen and superoxide to produce hydrogen peroxide involves the organelle
melanosome. As a result, melanosomes constantly become more structurally, and functionally
disordered, which generates higher levels of ROS that increases hydrogen peroxide stress at
melanoma cells [12]. Cells mechanism in response to peroxide stress have shown that normal
melanocytes can efficiently abrogate the peroxide stress, while this ability is seriously impaired in
melanoma cells, which evoking higher levels of reactive oxygen species (ROS).
Additionally, UVR has also been known to be associated with the development of skin
malignancies, as it causes skin inflammation by releasing inflammation mediators like cytokines
(1L-1 and 1L-6), which further generates great levels of ROS (i.e., H2O2) and induces oxidative
stress. Elevated ROS induces various oxidative DNA damage such as a mutagenic lesion at 8-oxodihydro-2’-deoxyguanine (8-oxo-dG) which is directly repaired by the DNA base excision-repair
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pathway [12]. In addition to environmental exposure cytotoxicity, organs encounter reactive
oxidants from internal metabolism.
It has been well documented that APE/Ref-1 is highly sensitive to both intracellular and
extracellular environments as it is an adaptive response to oxidative stress. Elevated levels of
reactive oxygen species (ROS) generate not only direct oxidization of amino acid residues at the
N-terminal domain of APE/Ref-1, but also increase subcellular localization of the protein [12].
APE/Ref-1 is an essential protein in protecting cells from ROS toxicity; however, overexpression
or activation of APE/Ref-1 as an adaptive response to prolonged oxidative stress transforms the
cellular signaling to proliferation and antiapoptotic phenotype [12]. The N-terminal redox function
of APE/Ref-1 is responsible for the activation of many transcription factors, including nuclear
factor-kB, HIF-α, and AP1, which have been well studied in many cancer cells. Therefore,
APE/Ref-1 may play an essential role in protecting cells from oxidative stress not only through
repairing oxidative DNA damage but also via regulating nuclear transcription factors and the
transcription of their downstream target genes [14]. It has been proposed that one of the redoxregulation mechanisms of APE/Ref-1 is based on oxidation and reduction of the thiol group of
cysteine residues [15]. According to the study, APE/Ref-1 might bind to thioredoxin, which serves
as a very potent reducing reagent [14]. By binding with thioredoxin, oxidized APE/Ref-1 will be
reduced, and the active form of APE/Ref-1 could bind to nuclear transcription factors. The other
underlying redox-regulation mechanism of the APE/Ref-1 is proposed to be through redox
regulation of many transcription factors (TFs) [10] with possible structural changes that are
associated with distinct redox status [14]. The loss of purine bases during DNA division leads to
the loss of potentially vital genetic information in cells. BER is the primary pathway to repair DNA
damages and to overcome the mutagenic and cytotoxic effects caused by spontaneous oxidation,
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non-enzymatic alkylation, and hydrolytic processes [11]. Apurinic/apyrimidinic endonuclease1/Redox factor-1 (APE/Ref-1) is a multifunctional protein, which is known to be essential in base
excision repair (BER) pathway signaling that is involved in DNA repair and nuclear redox
regulation of many transcription factors [12]. In redox mechanism, APE/Ref-1 regulates activation
of multiple cellular transcription factors including nuclear factor-κB (NF-κB) [16], signal
transducer and activator of transcription (STAT3), activator protein-1 (AP-1), Nrf-2 (Nuclear
factor erythroid 2-related factor-2).
APE/Ref-1 is one of the most promising proteins with the reduction-oxidation activity that can
influence multiple cancer survival mechanisms, including growth, proliferation, metastasis,
angiogenesis, and stress responses [17]. Studies on human melanoma cell lines have indicated the
role of APE1/Ref-1 as an adaptive response to oxidative stress, cancer progression,
chemoresistance, and increased morbidity [18]. The tumor microenvironment contains stromal
cells such as fibroblasts, endothelial cells, and macrophages [18]. The high-density tumorassociated macrophages correlate to poor prognosis, cancer progression, and secretion of several
inflammatory mediators, including TNF-α, interleukin-6 (IL-6), reactive oxygen species (ROS),
and nitric oxide (NO) [19]. The intracellular redox status of APE/Ref-1 appears to be a key
regulator of tumor cell growth [20], which makes the protein a promising candidate for anti-cancer
therapeutics [21]. As previously mentioned, human cells are constantly exposed to oxidative and
electrophilic chemicals both from endogenous and exogenous. Despite the important mechanism
of reactive oxygen species (ROS) and relative nitrogen species (RNS) in cellular redox hemostasis,
induced oxidative stress contributes to cell damage, chronic inflammation, and cancer initiation
[22].
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1.4

The role of Nrf-2 in redox regulation

Antioxidant response element (ARE) is a cis-regulatory element with specific DNA sequences at
upstream regulatory regions of genes that are responsible for encoding detoxifying enzymes and
cytoprotective proteins [23]. The antioxidant defense mechanism is found to be the major
protective response in maintaining redox hemostatic through upregulation of various enzymes and
cytoprotective compounds such as quinone oxidoreductase 1 (NQO1), superoxide dismutase
(SOD), glutathione S-transferase (GST), heme oxygenase-1 (HO-1) catalase and thioredoxin [22].
The three main cellular antioxidant responses, which found to be involved in maintaining the
cellular redox balance are Kelch-like Ech-associated protein 1 (Keap1), nuclear factor erythroid
2-related factor 2 (Nrf-2) and the antioxidant response element (ARE) [22]. Keap1 is constantly
bound with Nrf-2 in cytoplasm through ubiquitin-dependent proteasomal maintaining cells growth
at basal level. Under normal circumstances, Keap1 maintains cellular redox function of Nrf-2 by
acting as inhibitor and preventing its localization to nuclear via 26S proteasomal pathway. In this
mechanism, homodimerization of Keap 1 via its BTB to Neh2 domain of Nrf-2 (at ETGE and DLG
motif) maintains the steady-state of Nrf-2 at basal level [22]. Studies have proposed that the Cys273
and Cys288 at the linker intervening region (IVR) along with Cys151 at Broad complex, Tramtrack,
and Bric-a-Brac (BTB) domain of Keap 1 play important role in maintaining Nrf-2 at basal level
in the cytoplasm [24]. Upon oxidative stress, cysteine residues of Keap1 at BTB and IVR domain
are covalently modified, leading in conformational changes of Keap1 dimerization [25]. As a
result, Nrf-2 is escaped from Keap1-mediated degradation, translocate to the nucleus and activates
ARE-dependent antioxidant gene expression such as HO-1, NQO1, and several glutathione Stransferase components to regulate and maintain redox homeostasis and cell survival via formation
of the heterodimer with Maf protein [22]. Therefore, the redox balance of the cell is found to be
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necessary in Keap1-Nrf-2-ARE antioxidant pathway gene expression [22]. Nrf-2 is a bZip (basic
leucine Zipper) transcription factor that contains 605 amino acids with six conserved domains,
Neh1 to Neh6. Neh1 domain contains bZip motif that is found to be necessary for
heterodimerization with musculoaponeurotic fibrosarcoma (Maf) protein, allowing Nrf-2 to bind
with ARE activating gene. The N-terminal, Neh2 domain negatively regulates Nrf-2 transcriptional
activity by binding to Keap1 domain through DLG and ETGE motif. The Neh3 to Neh5 domains
are responsible in mediation of Nrf-2 transactivation activity. Lastly, thought the Neh6 domain,
Nrf-2 can be negatively regulated by Keap1-independent protein [22]. It has been proposed that
among six cysteine residues of Nrf-2, Cys183 and Cys506 are found to be necessary in their
antioxidant response [22]. Over the past few decades, many studies have highlighted the major
redox regulation function of APE/Ref-1 in response to oxidative stress, which can lead to
activation of Nrf-2 and its downstream target gens expression [26-28].

1.5

Development of novel APE/Ref-1 redox inhibitors

Cells are continuously subjected to reactive oxygen species produced by a normal metabolic
process, and APE/Ref-1 protects cells from ROS toxicity within cells mechanism [29]. As
mentioned earlier (1.2), APE/Ref-1 is also involved in response to elevated ROS caused by UVR
exposure. The role of APE/Ref-1 in inflammation and oxidative damage by cause of sunburn and
UVR exposure indicates interference with melanomagenesis by targeting APE/Ref-1 as a potential
preventive strategy [14]. The redox effector factor of APE/Ref-1 was first recognized by its DNA
base excision repair activity at its C-terminal domain, followed by its redox activity at N-terminal
domain which exhibits distinct redox regulation activity that facilitate DNA binding activity of
many transcription factors such as NF-kB [30], HIF-α [31], and AP-1 [32]. The APE/Ref-1 in
redox and repair function has made them a potential druggable target in various human
8

pathologies. However, little success has been made over the past two decades on developing potent
inhibitors targeting the DNA repair domain of APE/Ref-1. Therefore, major efforts have been
directed to identify and synthesize inhibitors to block the redox activity of APE/Ref-1 [11].
Studies have shown that the redox regulation activity of APE/Ref-1 is remarkably reduced by
either H2O2 oxidation or cysteine replacement by direct mutagenesis [33]. It has been proposed
that APE/Ref-1 might regulate the binding activity of transcription factors via maintaining them
at reduced state by reduced cysteine residues, specially Cys65 and Cys93 at its redox domain [34].
Studies have proposed that Cys65 serves as the nucleophilic residue in the reduction of disulfide
bonds within reduced transcription factors by APE/Ref-1 [17].
Recently, high demand virtual screening (VS) of three-dimensional protein structure by chemical
libraries has delivered rapid drug discovery development using docking strategy. The diverse
compound screening ability of VS has brought numbers of success drug discoveries such as E3330
[12]. Luo et al. [35] reported a promising redox inhibitors of APE/Ref-1, [(2E)-3-[5-(2,3dimethoxy-6-methyl-1,4- benzoquinone)]-2-nonyl-2-propenoic acid, also known as E3330. E3330
is a known promising clinically available APE1 redox-specific inhibitor, which has shown
stimulation of lipopolysaccharide (LPS) macrophages [18]. The compound was first known as NFkB inhibitor, but more studies revealed its novel mechanism by Matrigel assays and aortic ring
formation assays [17]. In this mechanism, E3330 suppresses the secretion of inflammatory
cytokines such as tumor necrosis factor-α (TNF-α), interleukin (IL-6) and IL-12 and inflammatory
mediators nitric oxide (NO) as well as the LPS-stimulated cells [18]. The compound successfully
inhibits APE/Ref-1 redox regulation function both in vitro and in vivo by blocking Endothelial
colony forming cell (ECFC) angiogenesis [17]. Downregulation of the LPS-dependent expression
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of inducible nitric oxide (iNOS) has also been indicated by E3330 inhibitor. Therefore, E3330 has
been known as a potent candidate in inflammatory response suppression, which provides a novel
therapeutic strategy for the inhibition of tumor-associated macrophages [18].
In our previous studies obtained by Yang et al. [12] group, a sophisticated computer program, ICM
software developed by MolsSoft L.L.C [36, 37] was used to model a three-dimensional structure
of APE/Ref-1. The software identified a potent druggable pocket located at the redox regulation
domain of APE/Ref-1 Conducting extensive virtual docking of over 3-million compounds using
the ICN database they identified potent lead compounds with successful docking into the Nterminal redox regulation domain of the APE/Ref-1. Using further cell-based bioactivity screening,
our group successfully developed R21, our lead APE/Ref-1 inhibitor with promising antimelanoma activity [38]. Our group further synthesized R21-OH, one of the analogs of R21, with
improved water solubility compared to its parental compound, R21. Our promising compound,
R21-OH, exhibited significant anti-melanoma activities at very low concentration (<5 µM)
compared to the other well studied APE/Ref-1 inhibitors such as E3330 and E2009. One of the
objectives of this study is to utilize a structure-based strategy using R21-OH as our lead promising
inhibitor to determine the binding characteristics of novel APE/Ref-1 inhibitors with the protein,
which will shed lights on design and development of more potent small molecular binders. In
addition, in our previous studies by Yang et al. [12] group, the two potent compounds, 2010-05
and SY598-21, also exhibited promising APE/Ref-1 redox inhibitory and anti-tumor activity in
vitro. The previous MTT results of our promising compound exhibited high cytotoxicity to human
melanoma cell line, A375, with improved water solubility compared to E3330. Taking these
candidates as lead compounds, we will determine the binding characteristics of APE/Ref-1 in order
to block the protein redox activity.
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Studies on nuclear transcription factors, have revealed mediated signaling of Nrf-2 on a set of
antioxidant proteins via binding to antioxidant response elements [39]. In addition to the DNA
repair activity of APE/Ref-1, the redox regulation of the protein via cysteine residues has shown
the significant role in reducing transcription factors such as Nrf-2, enhancing their binding to target
gene promoter [40]. Our previous studies on co-immunoprecipitation assays revealed a direct
binding interaction between APE/Ref-1 and Nrf-2. In our study, we will further determine if the
binding of APE/Ref-1 with Nrf-2 is redox-dependent or not.
Elevated Ref-1 levels and its abnormal cellular location is associated with many human tumors
including brain, cervical, pediatric rhabdomyosarcomas, prostate, epithelial ovarian cancers, and
germ cell tumors[41-45]. Upregulation of APE/Ref-1 protects cells from various pro-apoptosis
stimuli including oxidative stresses, chemotherapeutic drugs and radiation treatment [46-48].
Down-regulation of APE/Ref-1 expression is associated with sensitization of cells to induced
apoptosis both in vitro [49, 50] and in vivo[51, 52]. These results suggest that drugs targeting
APE/Ref-1 and especially the Ref-1 activity might be useful in combating cancer and, indeed,
compounds impairing APE/Ref-1-mediated signaling have enhanced therapeutic efficacies in
many human tumors [53, 54]. Moreover, pro-apoptotic effects of APE/Ref-1 are associated with
p53 regulation [55-57]. In addition, elevated APE/Ref-1 is closely associated with increased
metastatic potential owing to redox activation of nuclear transcription factors such as Nrf-2,
STAT3, NF-κB, and AP-1 [58-62]. Recent genome-wide analyses and proteomic studies revealed
an important role of APE/Ref-1 in regulating many biological processes, such as mitochondrial
function, cytoskeletal structure, and rRNA quality control [63-65]. It thus is clear that APE/Ref-1
is an attractive target for the development of new cancer preventive and therapeutic strategies [43,
65, 66]. The most potent APE/Ref-1 inhibitor developed by our group using structure-based

11

approach showed promising anti-melanoma activities both in vitro and in vivo. Taking this
candidate as our lead compound, we aim to determine the binding characteristics of APE.Ref-1
with our novel inhibitor and further develop more novel APE/Ref-1 inhibitors for human
melanoma therapy. We also aim to conduct experimental strategies to understand the direct
interaction mechanism and the redox regulation of APE/Ref-1 protein to nuclear transcription
factors.
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2 Chapter 2
2.1

Methodology

2.1.1 Overexpression of ∆40APE-1wt protein
The cDNA encoding a N-terminal truncated APE-1wt protein lacking the first 40 amino acid
residues (Δ40APE-1wt 31.3 kDa) was cloned into the pGEX-6P1 vector. The plasmid was then
transformed into the one shot® BL21 Star

TM

(DE3) Chemically competent E. coli (44-0049;

ThermoFisher, Waltham, MA). Ampicillin resistant colonies appeared on LB plates containing)
by heat shock at 42 ℃ for 45 seconds. Cells were plated onto 100 µg/ml Ampicillin (A-301-100;
Gold Biotechnology, St. Louis, MO) after overnight incubation at 37 ℃.
A single colony was used to inoculate 10 ml of LB media with ampicillin (100 µg/ml) and grown
with shaking, overnight at 30 ℃. The pre-cultured bacteria were transferred to a 2800 ml flask
containing 1000 ml LB Media with Ampicillin (500 µg/ml) and incubated at 37 ℃ for ~3 hours.
Once the OD600 reached 0.6-0.8, 0.25 mM isopropyl-beta-D-thiogalactopyranoside (IPTG;
12481C50; Gold Biotechnology, St. Louis, MO) was used to induce expression of GST-Δ40APE1wt at 25 ℃ for 8 hours. The culture was then centrifuged at 5,000 rpm using ThermoScientificTM
Sorvall LYNX 4000 Superspeed Centrifuge for 15 minutes, and pellets were harvested and
resuspended in cold 1x phosphate-buffered saline (PBS, pH 7.4; 70011-044, Life technologies
corporation, NY). The expression of GST-∆40APE-1wt fusion protein was confirmed by 12% SDSpolyacrylamide gels. The resuspended pellets were lysed on ice via sonication at 70% amplitude
in 1X PBS with 1 second on and 1 second off for 5 minutes. The sample was centrifuged at 17,000
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rpm using ThermoScientificTM Sorvall LYNX 18,000 Superspeed Centrifuge for 45 minutes, and
the supernatant which contained GST-Δ40APE-1wt, was collected.
In order to purify the glutathione-S-transferase (GST) - ∆40APE-1wt fusion protein, Glutathione
Agarose Resin (G-250-50; Gold Biotechnology, St. Louis, MO) was added to the supernatant and
mixed on a roller at 4 ℃ for 4 hours. GS4B beads provide a reversible ligand binding with GSTtagged protein, which leads to a mild purification process without any effect neither on protein
structure nor its function. The supernatant and bead slurry were then added to gravity flow
columns, and the onspecifically-bound proteins from the resin were washed thoroughly with 20
times of beads volume of cold 1X PBS. The GST- ∆40APE-1wt protein was eluted from the column
using 25 mM Reduced Glutathione pH 8.0 (GSH; G-155-100; Gold Biotechnology, St. Louis,
MO). Buffer change of the eluates to 1X PBS was achieved using 10 kDa Vivaspin Ultrafiltration
centrifugal tubes.
PreScission Protease is a fusion protein of glutathione S-transferase (GST). The protease
recognizes explicitly the subset of sequences, which include the core amino acid sequence LeuPhe-Gln/Gly-Pro cleaving between the Gln and Gly residues. This sequence is present between
the GST moiety and the cloned ∆40APE-1wt. 40 μl of PreScission Protease was added to the sample
and incubated overnight at 4 ℃. The cleavage of GST-∆40APE-1wt protein was confirmed by
SDS-PAGE.
The cleaved protein sample was purified using a size exclusion HiLoadTM 16/600 SuperdexTM 75
pg (28-9893-33; GE Healthcare Bio-Science; Sweden) column equilibrated with Buffer A (20 mM
Tris/HCl, pH 8.00, 150 mM NaCl, Degassed/ filtered). Then, the column, and run in buffer A with
a flow rate of 1mL/min with the total run at 120 minutes. The absorbance at 280 nm was measured,

14

and fractions eluted at 40 minutes to 55 minutes (dimeric Δ40APE-1wt), 60 minutes to 72 minutes
(monomeric Δ40APE-1wt), and 108 minutes to 120 minutes (mainly GST) were collected. The
fractions were analyzed by 12% SDS-PAGE. A modified Laemmli sample buffer without 2Mercaptoethanol (β-Mercaptoethanol/ BME) was used to avoid disruption of ∆40APE-1wt dimers.
The ∆40APE-1wt protein was concentrated in 1X PBS buffer using 10 kDa Vivaspin Ultrafiltration
centrifugal tubes at 21,130 rcf and 4 ℃. Bradford assay was used to quantify the protein content
and ~7 mM concentrated ∆40APE-1wt protein stored at -80 ℃.

2.1.2 ∆40APE-1wt crystallization and X-ray crystallography
~7 mM ∆40APE-1wt protein was used to set up crystallization trails, in a 1:1 ratio with reservoir
solution. Hampton Research and Rigaku Reagents crystallization kits were used. Monoclinic
protein crystals were grown within in 3 days in sitting drops containing 0.2 M calcium chloride
dihydrate, and 20% (w/v) Polyethylene glycol (PEG) 3,350 by vapor diffusion at 20 °C.
Diffraction data were collected from single crystals, after a brief transfer to a suitable
cryoprotectant (20% glycerol with the reservoir solution) using the X-ray diffraction system (D8
Venture Diffraction System, Bruker AXS Inc.) at our home institute and processed using
PROTEUM2 (Bruker AXS Inc.). The model was then refined by the Refmac5. Initial phases were
determined by Dr. Rahighi et al. by molecular replacement (MR) in the Molrep (CCP4), using the
human APE-1 structure (PDB: 5CFG). The Δ40APE-1wt was modeled in a pocket at the Mg2+
channel interface based on strong electron density followed by successful refinement of the
coordinates. Structure graphics and amino acid sequence alignment were prepared using PyMOL
(2.1.0 version; TM; Schrödinger, LLC).
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2.1.3 ∆40APE-1wt protein crystallization under oxidative condition
The N-terminal truncated protein lacking the first 40 amino acid residues, Δ40APE-1wt was
purified, oxidized with 200 µM H2O2, 10 µM Fe2+, and set up for crystallization trails as described
above. Monoclinic protein crystals were grown in a sitting drop containing 100 mM MES/ sodium
hydroxide pH 6.0, 20% W/V PEG 8,000, 200 mM calcium acetate by vapor diffusion at 20 °C.
Monoclinic crystals grew within a week. Diffraction data were collected from single crystals, after
a brief transfer to a suitable cryoprotectant (25% glycerol with the reservoir solution), on the Xray diffraction system (D8 Venture Diffraction System, Bruker AXS Inc.) at our home institute
and processed using PROTEUM2 (Bruker AXS Inc.). Initial phases were determined by molecular
replacement (MR) using PHASER from the CCP4 by Young-Woo Nam et al. Our previously
determined Δ40APE-1wt structure was used as a starting model to phase diffraction data. Prior to
modeling the rigid body refinement, solvent molecules were removed, and the crystallographic
model was constructed through iterative rounds of manual model-building using Coot3 and further
refinement by PHENIX60. The Δ40APE-1wt was modeled in a pocket at the Mg2+ channel interface
based on strong electron density in difference Fourier maps and followed by successful refinement
of the coordinates. The crystallographic statistics for data collection and model refinement are
summarized in Supplementary Table 1. Structure graphics, and amino acid sequence alignment
were prepared using PyMOL (2.1.0 version; TM; Schrödinger, LLC).

2.1.4 Structural study of ∆40APE-1wt after co-incubation with APE/Ref-1
inhibitor R21-OH
To determine the binding characteristics of Δ40APE-1wt, co-crystallization with our lead APE/Ref1 inhibitor, R21-OH was performed. The Δ40APE-1wt protein was expressed and purified as
previously described. Approximately 5.7 mM concentrated purified protein was subjected for co-
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incubation with our potent APE/Ref-1 inhibitor, R21-OH. The protein complex was mixed with
R21-OH (50 mM) and was set up for crystallization in a 1:1 ratio with reservoir solution. Protein
crystals of the protein complex were grown in sitting drops by vapor diffusion at 20 °C. Monoclinic
protein crystals were grown within a week in sitting drops containing 0.2 M sodium chloride, 0.1
M HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) pH 7.5, 20% (w/v) PEG 3,350
by vapor diffusion at 20 °C.
Diffraction data were collected from single crystals, after a brief transfer to a suitable
cryoprotectant (20% glycerol with the reservoir solution) using the X-ray diffraction system (D8
Venture Diffraction System, Bruker AXS Inc.) at our home institute and processed using
PROTEUM2 (Bruker AXS Inc.). The model was then refined by the Refmac5. Initial phases were
determined by Dr. Rahighi et al. by molecular replacement (MR) in the Molrep (CCP4), using the
human APE-1 structure (PDB: 5CFG). The Δ40APE-1wt was modeled in a pocket at the Mg2+
channel interface based on strong electron density followed by successful refinement of the
coordinates. Structure graphics and amino acid sequence alignment were prepared using PyMOL
(2.1.0 version; TM; Schrödinger, LLC).

2.1.5 Crystal soaking analysis of ∆40APE-1wt with APE/Ref-1 inhibitor R21OH
Monoclinic protein crystals were grown in 0.2 M sodium chloride, 0.1 M HEPES pH 7.5, 20%
(w/v) PEG 3,350. within 3 days at 20 °C. For “soaking” experiments, preformed crystals of the
∆40APE-1wt protein were incubated with our potent inhibitor at different concentrations of 10, 20,
and 50 mM.
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2.1.6 Detection of ∆40APE-1wt dimer formation using Western Blot
The Δ40APE-1wt protein was expressed and purified as previously described. Approximately 0.3
µg/ml ∆40APE-1wt was incubated with 10mM TCEP (77720; Thermo Scientific, Rockford, IL)
overnight. After washing out the reducing reagent, 5, 10, 20, and 50 of R21-OH and 1% DMSO
(20688; Thermo Scientific, Rockford, IL) as a positive control was incubated with the reduced
∆40APE-1wt overnight. Samples were then mixed with 5X denaturing loading buffer containing
10% SDS, loaded and separated on SDS-polyacrylamide gels. Overnight transfer was performed
on an Immobilon-PSQ polyvinylidene difluoride (PVDF) membranes (ISEQ00010; Merck KGaA,
Darmstadt, Germany).
To determine whether R21-OH facilitates dimerization of ∆40APE-1wt, we further incubated
∆40APE-1wt with 10 mM Tris (2-carboxyethyl) phosphine (TCEP; 77720; Thermo Scientific,
Rockford, IL), at different time points to determine whether R21-OH facilitates dimerization of
∆40APE-1wt. Then the reducing reagent is washed out and equal amount of ∆40APE-1wt protein
was incubated for another 24 hours with different concentrations of R21-OH and the negative
control was treated with the same amounts of DMSO solution. Samples were then filtered, loaded
and separated on SDS-polyacrylamide gels using 5X native dye containing 10% Sodium dodecyl
sulfate (SDS), then transferred to Immobilon-PSQ polyvinylidene difluoride (PVDF) membranes
(ISEQ00010; Merck KGaA, Darmstadt, Germany). Western blots were blocked using 10% nonfat milk, and then the membranes were incubated with the primary rabbit monoclonal anti-human
Ape1 (1:10,000, #4128; Cell Signaling Technology, Danvers, MA) antibody overnight at 4 ºC
followed by secondary anti-rabbit antibody (1:2,000 Cell Signaling Technology, Danvers, MA)
for 1 hour at room temperature. Blots were washed extensively with TBS-T after each antibody
incubation. Labeled bands were detected using SuperSignal horseradish peroxidase
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chemiluminescence reagents (1859674; 1859675; Thermo Fisher Scientific, Waltham, MA) and
the bands were analyzed using the Bio-Rad ChemiDoc XRS+ System and normalized to ∆40APE1wt levels.

2.1.7 Overexpression of ∆40APE-1C138A mutant protein
The single-cysteine mutant APE-1 proteins tagged at the N-terminus with GST plasmid construct
were sent for site-directed mutagenesis of cysteine 138 to alanine (GeneScript, Piscataway, NJ),
the protein was expressed as described previously. In a brief, a single-cysteine mutant protein, was
cloned into the pGEX-6P1 vector. The ∆40APE-1C138A construct was then transfected into the one
shot® BL21 Star

TM

((λDE3) Chemically competent E.Coli (44-0049; ThermoFisher, Waltham,

MA) by heat shock at 42 ℃ for 45 seconds. Selected colonies were inoculated and grown overnight
at 30 ℃ in 50 mL Luria broth (LB) medium containing 100 μg/mL ampicillin (A-301-100; Gold
Biotechnology, St. Louis, MO). 5 ml of pre-cultured bacteria were transferred to a 2800 ml flask
containing 1000 ml LB Media with ampicillin (500 µg/ml) and incubated at 37 ℃ for 3 hours.
Once the OD600 reached 0.6-0.8, induction was performed with 0.25 mM isopropyl-beta-Dthiogalactopyranoside (IPTG; 12481C50; Gold Biotechnology, St. Louis, MO) at 25 ℃ for 8
hours. The culture was then centrifuged at 5,000 rpm using ThermoScientificTM Sorvall LYNX
4,000 Superspeed Centrifuge for 15 minutes, and pellets were collected and resuspended in cold
Phosphate Buffered Saline (1X PBS, pH 7.4). The expression of fusion protein before and after
induction is confirmed by 12% SDS-polyacrylamide gels. The resuspended pellets were lysed on
ice via sonication at 70% amplitude in 1X PBS with 1 second on and 1 second off for 5 minutes.
The sample was centrifuged at 17,000 rpm using ThermoScientificTM Sorvall LYNX 4000
Superspeed Centrifuge for 45 minutes, and the supernatant which contained the protein of interest,
was collected.
19

2.1.8 Pull down assay using GST-∆40APE-1wt and GST-∆40APE-1C138A
protein
Nuclear extraction of melanoma A375 cells were treated with 100 µM H2O2 for 72 hours in serumfree media and were collected via centrifugation and resuspended in buffer A (10 mM HEPES, pH
7.9, 10 mM KCl, 0.150 mM MgCl2, 0.5 mM DTT, 0.2 mM PMSF) with 1% protease inhibitor
cocktail (PIC) and allowed to swell for 10 minutes. 10% NP-40 was added and vortexed to lyse
the cells. The sample was spun down at maximum speed for 30 seconds to collect the cytosolic
fraction. The pelleted nuclei were resuspended and incubated in buffer C (20 mM HEPES, 20%
glycerol, 0.42 M NaCl, 0.15 mM MgCl2, 0.2 mM EDTA, 0.5 mM DTT, and 0.2 mM PMSF) with
1% PIC then placed in the centrifuge at maximum speed for 30 minutes to isolate the nuclear
proteins. Buffer D (20 mM HEPES, 20% glycerol, 50 mM KCl, 0.5 mM EDTA, 0.5 mM DTT,
and 0.2 mM PMSF) was then added to dilute the nuclear samples. Protein concentration was
determined by Bradford assay. GST-∆40APE-1wt and GST-∆40APE-1C138A purified protein (100
µg) were oxidized separately overnight by incubation with hydrogen peroxide (H2O2, 200 µM)
and Fe2+ (5 µM or 10 µM) respectively. After washing out the hydrogen peroxide and Fe2+,
samples were incubated overnight with equal amounts of nuclear extractions on Glutathione
Agarose Resin (G-250-50; Gold Biotechnology, St. Louis, MO). Elution was performed using
25mM Reduced Glutathione pH 8.0 (GSH; G-155-100; Gold Biotechnology, St. Louis, MO),
followed by buffer change to PBS.

Samples were then loaded and separated on SDS-

polyacrylamide gels, then transferred to Immobilon-PSQ polyvinylidene difluoride (PVDF)
membranes (ISEQ00010; Merck KGaA, Darmstadt, Germany) for Western blotting analysis.
Membranes blocked by 10% non-fat milk, were further incubated with the primary antibodies for
1 hour at room temperature or overnight at 4 ºC, followed by secondary antibody incubation for 1
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hour at room temperature. Membranes were washed extensively with TBS-T (Tris‐buffered saline
containing 0.1% Tween 20) after each antibody incubation. The specific bands were detected using
SuperSignal horseradish peroxidase chemiluminescence reagents (1859674, 1859675; Thermo
Fisher Scientific, Waltham, MA) and images were captured and analyzed using the Bio-Rad
ChemiDoc XRS+ System.

2.1.9 Effect of cysteine 138 in APE/Ref-1 protein dimerization ∆40APE-1C138A
To further study the role of Cysteine 138 in the dimerization of APE/Ref-1 protein, we generated
a single Cys138 mutant ∆40APE-1C138A, which cysteine was replaced by redox-inactive alanine
using site-directed mutagenesis as directed by the manufacturer (GeneScript, Piscataway, NJ). The
∆40APE-1C138A construct was then transfected into the one shot® BL21 StarTM ((λDE3)
Chemically competent E.Coli (44-0049; ThermoFisher, Waltham, MA), and subjected for
expression and purification as described previously in section 2.1.7.
To determine the effect of Cys138A on protein dimerization under oxidative condition, the purified
∆40APE-1C138A protein was first incubated with 200 µM H2O2 overnight. After washing out H2O2
using

EMD

Millipore™ Amicon™

Ultra-0.5

Centrifugal

Filter

Units

(UFC501024;

ThermoFisher, Waltham, MA), equal amount of ∆40APE-1wt protein samples in PBS were
incubated with different concentrations R21-OH for 24 hours. The sample incubated with the same
amounts of DMSO solution was defined as control. After incubation, samples were then washed,
filtered, and subjected for SDS-polyacrylamide gels using 5x native dye-containing 10% sodium
dodecyl sulfate (SDS). Samples were then transferred to Immobilon-PSQ polyvinylidene
difluoride (PVDF) membranes (ISEQ00010; Merck KGaA, Darmstadt, Germany) for blotting and
imaging using specific antibodies as described in 2.1.6.
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2.2

Cell lines, chemicals and reagents

The human melanoma cell line A375 was obtained from American Type Culture Collection
(ATCC; Manassas, VA), and was cultured in Dulbecco’s Modified Eagle’s Medium (DMEM;
#11995073; Gibco, Waltham, MA) with 10% fetal bovine serum (FBS; #26140079; Gibco,
Waltham, MA), or Tumor Specialized Media with 2% FBS (WM3211, 1205Lu).
Novel APE/Ref-1 inhibitor, R21-OH, designed and synthesized by Yang et al. and Parang et el.
research groups respectively, were dissolved in 100 mM DMSO (20688; Thermo Scientific,
Rockford, IL) for stock concentration. Further, serial dilutions of R21-OH were used for
experimental use.

2.2.1 Antibodies
Mouse monoclonal anti-human STAT3, Nrf-2 (A-10) (sc-293151; sc365949; Santa Cruz
Biotechnology, Inc. Dallas, TX) and rabbit monoclonal anti-human Ape1 (#4128; Cell Signaling
Technology, Danvers, MA) antibodies were used as primary antibodies; horseradish peroxidaselabeled anti-mouse and anti-rabbit (1:5,000; 1:2,000 Cell Signaling Technology, Danvers, MA)
was used as the secondary antibodies.

2.3

Surface Plasmid Resonance (SPR)

Purified recombinant GST-∆40APE-1wtprotein (50 μg/ml) was conjugated on GST sensor chip
(Nicoya Lifesciences Open SPR) using GST ligand wizard immobilization (Instrument standard
procedures) followed by 50 μg/ml GST blocking. Serial dilution of R21-OH analyte (0.25, 0.5,
and 1 mM in running buffer containing 1.02% PBS with 0.5% Dimethylformamide (DMF) and
0.5% Methanol (MeOH) was injected at a flow rate of 20 μl/min sequentially into the chamber in
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running buffer (1.02% PBS, 0.5% DMF and 0.5% MeOH). The interaction of GST fusion protein
with R21-OH was detected by OpenSPR™ (Nicoya Lifesciences) at 20 °C and allowed to associate
and dissociate for 120 seconds and 480 seconds, respectively. The surface chip was regenerated
with 25 mM GSH solution in 0.5 M Tris-HCl pH 8.0 at flow rate of 150 μl/min. The close curve
fitting to the sensorgrams was calculated by global fitting curves (1:1 Langmuir binding model).
The data was retrieved and analyzed with TraceDraw software.
Using the same techniques and running buffer, the purified recombinant mutated GST-∆40APE1C138A (50 μg/ml) protein was conjugated on GST sensor chip of OpenSPR™ (Nicoya
Lifesciences) and interactions between the ligand and the analyte was detected. The close curve
fitting to the sensorgrams was calculated by global fitting curves (1:1 Langmuir binding model).
The data was retrieved and analyzed with TraceDraw software.
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3 Chapter 3
3.1

Results

3.1.1 ∆40APE-1wt protein expression
First, N-terminally truncated APE/Ref-1 protein lacking the first 40 amino acid residues (∆40APE1wt) was cloned into the pGEX-6P1 vector to express the GST-tagged fusion protein. As shown in
Figure 3.1, we have successfully expressed GST-∆40APE-1wt protein after induction with 0.25
mM IPTG. The targeted mass of 56.5 kDa is confirmed using 12% SDS-polyacrylamide gel. The
GST tag was then subjected for cleavage using PreScission Protease enzyme (<0.1 EU/µg) at 4
℃. The 12% SDS-polyacrylamide gel results of the affinity chromatography shown in Figure 3.2,
confirms partial digestion of the GST-tag from ∆40APE-1wt with the target mass of 31.3 kDa after
24 hours incubation.
After GST tag cleavage, size exclusion chromatography was performed to separate the molecules
based on their molecular weight. Samples were run through the HiLoadTM 16/600 SuperdexTM 75
pg (28-9893-33; GE Healthcare Bio-Science; Sweden) column, and the two fraction pecks shown
in Figure 3.3 A, were collected in running buffer, 20 mM Tris/HCl, pH 8.00, 150 mM NaCl.
The fraction collected form A32-A37 (from 60 minutes to 72 minutes) shown in Figure 3.3 A, is
confirming the band for ∆40APE-1wt protein by 12% SDS-polyacrylamide gel shown in Figure
3.3 B, and by western blot using rabbit monoclonal anti-human Ape1 primary antibodies
respectively shown in Figure 3.3 C.
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Figure 3.1 GST-∆40APE-1wt expression after induction with 0.25 mM IPTG with 12%
SDS-polyacrylamide gel. Considering the molecular weight of 31.3 kDa for truncated
∆40APE-1wt with 25 kDa GST-tag, the 56.5 kDa band confirmed targeted mass for
GST-∆40APE-1wt.

25

M

kDa

GST-∆40APE-1wt
PreScission Protease

∆40APE-1wt
GST- tag

Cleavage

57
46

32

25

Figure 3.2 Partial digestion of ∆40APE-1wt protein from Gst-tag (25 kDa) after
incubation with PreScission Protease enzyme was confirmed by 12% SDSpolyacrylamide gels. Targeted mass of 31.3 kDa was confirmed for cleaved ∆40APE1wt protein.
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Figure 3.3 A) Size exclusion chromatography of the cleaved samples. Samples were
injected to the HiLoadTM 16/600 SuperdexTM 75 pg (28-9893-33; GE Healthcare
Bio-Science; Sweden) column in running buffer containing 20 mM Tris/ HCL pH 8.0,
150 mM NaCl. The ∆40APE-1wt peak was confirmed by 12% SDS-polyacrylamide gel,
and Western blot using APE1 antibody. B) Confirmation of the ∆40APE-1wt peak at
A30-37 by 12% SDS-polyacrylamide gel. The targeted molecular weight of 31.3 kDa
confirmed the band for ∆40APE-1wt. C) Confirmation of the ∆40APE-1wt protein
fraction peak at A30-37 by western blot using APE1 antibody.

27

3.1.2 Crystal structure of ∆40APE-1wt
7 mM ∆40APE-1wt protein was subjected for crystallization. We have successfully obtained
∆40APE-1wt crystals grown in sitting drops by vapor diffusion at 20 °C. Figure 3.4, shows an
overview of some of the obtained ∆40APE-1wt crystals in the specified resveratrol solution with
their obtained diffraction pattern. The ∆40APE-1wt crystal grown in sitting drop containing 0.2 M
calcium chloride dihydrate, and 20% (w/v) polyethylene glycol (PEG) 3,350 shown in Figure 3.5
A), was subjected for screening using in house D8 Venture Diffraction System, Bruker AXS Inc.
Figure 3.5 B), shows diffraction pattern of the subjected crystal with the specified unit cells that
was collected with resolution up to 1.57Å. The data was processed using PROTEUM2 (Bruker
AXS Inc.), and unit cells were defined as monoclinic with space group C2. The initial phases were
determined by Dr. Rahighi et al. by molecular replacement (MR) in the Molrep (CCP4), using the
already available human APE-1 structure (PDB: 5CFG). The Δ40APE-1wt was modeled in a pocket
at the Mg2+ channel interface based on strong electron density followed by successful refinement
by the Refmac5. Structure graphics and amino acid sequence alignment were prepared using
PyMOL (2.1.0 version; TM; Schrödinger, LLC). As can be seen in Figure 3.6, our solved
Δ40APE-1wt crystal structure highlighted in blue is overlapping with the already available human
APE-1 structure (PDB: 5CFG) highlighted in green.
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∆40APE-1wt Crystals
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Diffraction pattern

Salt:
N/A
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Precipitant:
20% (w/v) PEG 3350

Crystal specifications
Resolution:

1.9Å

Unit Cells:
a: 86.23Å
b: 45.69Å
c: 78.52Å

": 90.00°
%:105.24°
&: 90.00°

Space Group:
Monoclinic C

Salt:
N/A
Buffer:
200mM calcium chloride
Precipitant:
20% W/v PEG 3,350

Resolution:

2.22Å

Unit Cells:
a: 77.09Å
b: 44..85Å
c: 77.51Å

": 90.00°
%: 92.20°
&: 90.00°

Space Group:
Monoclinic C

Salt:
0.2M calcium acetate
Hydrate
Buffer:
20% w/v polyethylene
glycol 3350 pH 7.5

Resolution:

1.74Å

Unit Cells:
a: 75.71Å
b: 44.75Å
c: 76.73Å

": 90.0°
%: 91.90°
&: 90.0°

Space Group:
Monoclinic C

Precipitant:
N/A

Figure 3.4 Overview of ∆40APE-1wt crystals. The reservoir solution for each obtained
crystal along with diffraction specification is mentioned in the Figure.
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A

∆40APE-1wt Crystal

Resveratrol solution
Salt:
0.2 M calcium chloride
dihydrate
Buffer:
N/A
Precipitant:
20% (w/v) polyethylene
glycol 3,350

B

Diffraction pattern

Crystal specification
Resolution : 1.57Å
Unit Cells:
a: 75.71Å
b: 44.75Å
c: 76.73Å

": 90.0°
&: 91.90°
': 90.0°

Space Group :
Monoclinic C2
Figure 3.5 A) ∆40APE-1wt crystal grown by vapor diffusion at 20 °C in sitting drop
containing 0.2 M calcium chloride dihydrate, and 20% (w/v) polyethylene glycol
(PEG) 3,350 was subjected for screening. B) Diffraction pattern obtained from crystal
grown in sitting drop containing 0.2 M calcium chloride dihydrate, and 20% (w/v)
polyethylene glycol (PEG) 3,350 was collected in house using D8 Venture Diffraction
System, Bruker AXS Inc and the data was processed using PROTEUM2 (Bruker AXS
Inc.). The data was collected with resolution up to 1.57Å and the unit cells were defined
as monoclinic C2.
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Figure 3.6 ∆40APE-1wt monomer structure. As can be seen in the figure, our solved
structure of ∆40APE-1wt protein highlighted in blue is overlapping with the reported
APE/Ref-1 structure in protein data bank (PDB: 5CFG), highlighted in green.
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3.1.3 Co-incubation of ∆40APE-1wt with novel APE/Ref-1 inhibitor, R21-OH
We then conducted co-crystallization of ∆40APE-1wt with our novel design APE/Ref-1 inhibitor
R21-OH (50 µM). Figure 3.7 shows some of the obtained co-crystals with their specified
resveratrol solution and their diffraction pattern specifications. The crystal grown in sitting drop
containing 0.2 M calcium chloride, 0.1 M HEPES pH 7.5 and 20% (w/v) polyethylene glycol
(PEG) 3,350, shown in Figure 3.8 A), was subjected for screening using in house D8 Venture
Diffraction System, Bruker AXS Inc. As can be seen in Figure 3.8 B), diffraction pattern of the
subjected crystal was collected with resolution of 2.48Å . The data was processed using
PROTEUM2 (Bruker AXS Inc.), and unit cells were defined as monoclinic with space group C2.
The initial phases were determined by Dr. Rahighi et al. by molecular replacement (MR) in the
Molrep (CCP4), using the already available human APE-1 structure (PDB: 5CFG). The Δ40APE1wt was modeled in a pocket at the Mg2+ channel interface based on strong electron density
followed by successful refinement by the Refmac5. Structure graphics and amino acid sequence
alignment were prepared using PyMOL (2.1.0 version; TM; Schrödinger, LLC).
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Figure 3.7 Overview of co-incubation of ∆40APE-1wt with 50 µM R21-OH. The
reservoir solution for each obtained co-crystal along with diffraction specification is
mentioned in the figure.
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Co-crystallization of
∆40APE1wt
With 50µM R21-OH

Resveratrol solution
Salt:
0.2M Sodium Chloride
Buffer:
0.1M HEPES pH 7.5
Precipitant:
20% (w/v) PEG 3,350

B

Diffraction pattern
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Resolution : 2.48Å
Unit Cells:
a: 75.9Å
b: 93.5Å
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Figure 3.8 A) Co-incubated ∆40APE-1wt protein crystal in 50 µM R21-OH, obtained
from vapor diffusion at 20 °C in sitting drop containing 0.2 M calcium chloride, 0.1 M
HEPES pH 7.5 and 20% (w/v) polyethylene glycol (PEG) 3,350 was subjected for
screening. B) Diffraction pattern was collected in house using D8 Venture Diffraction
System, Bruker AXS Inc and the data was processed using PROTEUM2 (Bruker AXS
Inc.). The data was collected with resolution of 2.48Å and the unit cells were defined
as monoclinic C2.
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3.1.4 Novel APE/Ref-1 inhibitor, R21-OH, facilitates dimerization of
∆40APE-1wt protein at Cys 138 residue
Figure 3.9 shows our solved structure of ∆40APE-1wt with R21-OH (50 µM). The model was
refined by the Refmac5, and the molecular replacement (MR) was performed by Molrep (CCP4)
software, using already available human APE-1 structure (PDB: 5CFG). The Δ40APE-1wt was
modeled in a pocket at the Mg2+channel interface based on strong electron density in difference
Fourier maps and followed by successful refinement of the coordinates. Our solved structure
shown in Figure 3.9 failed to identify any binding of R21-OH with ∆40APE-1wt protein. However,
the formation of the disulfide bond at cysteine 138 residues between the two ∆40APE-1wt
monomers was observed.
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Cys138

Figure 3.9. ∆40APE-1wt crystal structure obtained from co-incubation with 50 µM R21OH. Our solved co-incubated structure failed to identify any binding of R21-OH with
∆40APE-1wt. However, the formation of disulfide bond is evident at Cys138.
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3.1.5 Crystal structure of APE/Ref-1 dimer under oxidative stress
~5 mM ∆40APE-1wt protein was subjected for crystallization under oxidative condition with H2O2
(200 µM)/Fe2+ (10 µM) for crystallization. Successfully obtained crystals in oxidative condition
with their diffraction specifications are shown in Figure 3.10. One of the obtained oxidized
∆40APE-1wt crystals grown in sitting drop containing 100 mM MES/NaOH pH 6.0, 0.1 M HEPES
pH 7.5, 20% w/v PEG 8,000, and 200 mM calcium acetate (Figure 3.11 A) was subjected for
screening using in house D8 Venture Diffraction System, Bruker AXS Inc. Figure 3.11 B) shows
the obtained diffraction pattern with resolution of 2.48Å. The data collection was processed using
PROTEUM2 (Bruker AXS Inc.), and unit cells were defined as monoclinic with space group C2.
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∆40APE-1wt crystals in oxidative
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Figure 3.10 Overview of ∆40APE-1wt crystallization in oxidized condition. The
reservoir solution for each obtained crystal along with diffraction pattern and
specifications are mentioned in the Figure.
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Oxidized ∆40APE1wt
Crystal With 200µM H2O2
+10µM Fe2+

Resveratrol solution
Salt:
100mM MES/ sodium
hydroxide pH 6.0
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Precipitant:
20% (w/v) PEG 8000,
200mM calcium acetate

B

Diffraction pattern

Data Analysis
Resolution : 2.3Å
Unit Cells:
a: 76.52Å
b: 44.87Å
c: 77.44Å

": 90.0°
&: 92.21°
': 90.0°

Space Group :
Monoclinic C2

Figure 3.11 A) ∆40APE-1wt crystals formed under oxidative condition in sitting drop
containing 100 mM MES/ sodium hydroxide pH 6.0, 0.1 M HEPES pH 7.5, and 20%
(w/v) polyethylene glycol (PEG) 8,000 with 200 mM calcium acetate. B) X-ray
diffraction data were collected using D8 Venture Diffraction System (Bruker AXS Inc.)
and further processed using PROTEUM2 program (Bruker AXS Inc.). The crystal used
for data collection had a resolution of 2.3Å and the unit cells were defined as
monoclinic C2.
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3.1.6 Dimerization of ∆40APE-1wt protein under oxidative stress
The obtained crystal under oxidative stress was subjected for data collection. The initial phases
were determined by Young-Woo Nam et al. by molecular replacement (MR) in the Molrep (CCP4),
using the already available human APE-1 structure (PDB: 5CFG). The data was processed using
PROTEUM2 (Bruker AXS Inc.), and the unit cells were defined as monoclinic with space group
C2. Prior to modeling the rigid body refinement, solvent molecules were removed, and the
crystallographic model was constructed through iterative rounds of manual model-building using
Coot3 and further refinement by PHENIX60. The Δ40APE-1wt was modeled in a pocket at the Fe2+
channel interface based on strong electron density in difference Fourier maps and followed by
successful refinement of the coordinates. Structure graphics and amino acid sequence alignment
shown in Figure 3.12 were prepared using PyMOL (2.1.0 version; TM; Schrödinger, LLC). The
solved structure determined formation of disulfide bond between the Cys138 residues of two
APE/Ref-1 molecules (Figure 3.12). To the best of our knowledge, this is the first reported dimer
structure of APE/Ref-1 formed under oxidative condition.
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Cys138

Figure 3.12. Structure of ∆40APE-1wt protein under oxidative stress (200 µM H2O2/10
µM Fe2+). Formation of disulfide bond between the Cys138 residues of two APE/Ref1 molecules is evident in our solved structure. To the best of our knowledge, this is the
first reported dimer structure of APE/Ref-1 formed under oxidative condition.
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Table 1. Data collection and refinement of oxidized ∆40APE-1wt with 200 µM H2O2 +10 µM Fe2+)
Data collection

Oxidized ∆40APE-1wt
(200 µM H2O2 +10 µM Fe2+)

Wavelength

1.3134

Space group

C121

Unit cells (Å)

A=76.52, b=44.87, c=77.44 Å
1

Resolution (Å)

Total reflection

25.80.78 -2.3
(2.38-2.3)
41,170 (2823)

Unique reflection

11,765 (1096)

Completeness2

98.5 (92.4)

Multiplicity

3.5 (2.6)

Mean I/ σ(I)b

9.8 (3.2)

Rmergeb

0.101 (0.342)

b

0.995 (0.926)

CC1/2

Refinement
Resolution

25.8 - 2.3

No.of reflection

11883

R factor/ Rfree (%)

0.2027/ 0.2896

No. of atoms

2322

No. of solvents

128

RMSD from ideal values
Bond lengths (Å)

0.009

Bond angels (˚)

1.34

Ramachandran plot (%)

1
2

Favored

95.60

Allowed

4.4

Outlier

0

Calculated using XDS.
Values in parentheses are for the highest resolution shell
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3.1.7 The formation of ∆40APE-1wt dimer detected by western blot analysis
Figure 3.13 To determine whether R21-OH facilitates dimerization of APE/Ref-1, we conducted
western blot experiment by starting incubation of ∆40APE-1wt protein (0.5 mg) with 10 mM TCEP
(reducing reagent) at room temperature for 24 hours, 48 hours and 72 hours respectively. Samples
were collected for SDS-PAGE, followed by blotting with anti-APE/Ref-1 antibody. The bands
were scanned and analyzed by Bio-Rad ChemiDoc XRS+ system. Figure 3.13 A) shows the
western blot data of ∆40APE-1wt (0.5 mg) incubated with 10 mM TCEP. As shown in the results,
after incubation for 72 hours, majority of ∆40APE-1wt is presented with monomer form and the
conversion of dimer to predominant monomer state of ∆40APE-1wt protein is evident in reduced
condition (exposed with 10 mM TCEP). Figure 3.13 B) shows the co-incubated of the post treated
∆40APE-1wt protein with reducing reagent, followed by incubation with different concentrations
of R21-OH The bands were scanned and analyzed by Bio-Rad ChemiDoc XRS+ system and
normalized to ∆40APE-1wt levels. The experiment was conducted at least three times and the dimer
bands were normalized to ∆40APE-1wt levels. As can be seen the results shown in Figure 3.13 B).
As shown in the figure, ∆40APE-1wt protein is converted to dimer state after co-incubation with
R21-OH. Our results indicate that our potent inhibitor, R21-OH facilitates dimerization of
∆40APE-1wt in a dose dependent manner, which can be a novel APE/Ref-1 mechanism in antimelanoma mechanism.

43

A
10mM TCEP
Control

48hr

24hr

72hr

Dimers

Monomers

B
R21-OH µM

Dimers

Control

TCEP
10mM

DMSO

5

10

20

50

Fold of increase
(ratio of dimer to monomer)

2.0

1.34

1.5
1.0

1.09

1.20

5 µM

10 µM

1.18

1.00

0.5
0.0

DMSO

20 µM

50 µM

Dimerization of ∆40APE-1wt by R21-OH

Figure 3.13 A) shows our Western Blot experiment of ∆40APE-1wt co-incubated with
TCEP (10 mM reducing reagent) and is detected by anti-APE/Ref-1 antibody. As
shown in the results, after incubation with TCEP (10 mM) for 72 hours, majority of
∆40APE-1wt is presented with monomer form and the conversion of dimer to
predominant monomer state of ∆40APE-1wt protein is evident in reduced condition
(exposed with 10 mM TCEP). B) shows the results after incubation of the reduced
∆40APE-1wt protein with different concentrations of R21-OH. The protein is converted
to dimer state after co-incubation with R21-OH in a dose dependent manner. Our
results indicate that our potent inhibitor, R21-OH facilitates dimerization of ∆40APE1wt, which might be a novel mechanism of its anti-melanoma activities.
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3.1.8 ∆40APE-1C138A protein expression
In order to determine if the binding of ∆40APE-1wt with Nrf-2 was redox-dependent or not, we
constructed a redox-deficient APE/Ref-1 mutant with cysteine 138 replaced by alanine. The
∆40APE-1C138A mutant protein was expressed and purified in exactly the same way as ∆40APE1wt as mentioned in 2.1.1. The GST-∆40APE-1C138A protein was subjected for GST-tag cleavage
using in house PreScission Protease enzyme (<0.1 EU/µg) at 4 ℃. As shown in Figure 3.14 A) the
partial digestion of GST-tag protein is confirmed by 12% SDS-polyacrylamide gel. After GST-tag
cleavage, size exclusion chromatography is performed to separate the molecules based on their
molecular weight. Samples were run through the HiLoadTM 16/600 SuperdexTM 75 pg (28-989333; GE Healthcare Bio-Science; Sweden) column, in running buffer containing 20 mM Tris/HCl,
pH 8.00, 150 mM NaCl. The subjected fractions peck at 72 minutes to 84 minutes shown in Figure
3.14 B) were collected and as can be seen in Figure 3.14 C), samples were analyzed by 12% SDSpolyacrylamide gel.
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Figure 3.14 A) Partial digestion of GST-∆40APE-1C138A mutant protein by PreScission
Protease enzyme (<0.1 EU/µg). B) Size exclusion chromatography of the cleaved GST∆40APE-1C138A mutant protein. Samples were injected to the HiLoadTM 16/600
SuperdexTM 75 pg column in running buffer containing 20 mM Tris/ HCl pH 8.0, 150
mM NaCl. The subjected fractions peck at 72 minutes to 84 minutes confirmed
∆40APE-1C138A protein by 12% SDS-polyacrylamide gel (C). C) The targeted
molecular weight of 31.3 kDa confirmed the band for ∆40APE-1C138A.

46

3.1.9 ∆40APE-1C138A mutant protein failed to form dimerization under
oxidative condition and co-incubation with R21-OH
We conducted the same experiment mentioned before 2.1.6 using ∆40APE-1C138A mutant protein.
Figure 3.15 show our western blot experiment of ∆40APE-1C138A exposed with H2O2 (200 µM),
and different concentrations of the novel APE/Ref-1 inhibitor, R21-OH at room temperature
overnight. As can be seen in Figure 3.15, the distinct redox form of ∆40APE-1wt, was failed to
observe any dimer formation of ∆40APE-1C138A mutated protein under oxidative condition (200
µM H2O2), and with co-incubation with R21-OH for 12 hours. Based on the results shown in
Figure 3.15, the monomer remains the predominant form of ∆40APE-1C138A protein which
demonstrates the critical role of Cys138 in the dimerization of ∆40APE-1wt. Further study is
warranted to determine the role of Cys138 in the binding of Nrf-2 protein.
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Figure 3.15 ∆40APE-1C138A mutant protein exposed with H2O2 (200 µM), and different
concentrations of the novel APE/Ref-1 inhibitor, R21-OH at room temperature
overnight. The distinct redox form of ∆40APE-1wt shown in Figure 3.13 was failed to
observe any dimer formation of ∆40APE-1C138A mutated protein specially under
oxidative condition (200 µM H2O2), and with co-incubation with R21-OH for 12 hours.
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3.1.10 The binding of APE/Ref-1 with Nrf-2 was regulated in a redoxdependent manner
To investigate whether the signaling pathway from APE/Ref-1 to the nuclear transcription factors
is regulated in a redox-dependent manner, we performed GST pulldown analysis with the GST∆40APE-1wt protein and the nuclear extracts of melanoma cells. ∆40APE-1wt expressed and
purified as described before 2.1.1. Purified GST-∆40APE-1wt protein was oxidized by H2O2 (200
µM)/Fe2+(5 µM and 10 µM) overnight, followed by washing and centration spin to remove
H2O2/Fe2+. 100 µg of GST-∆40APE/Ref-1wt was immobilized on glutathione beads and incubated
with nuclear extraction of melanoma cells at room temperature overnight [67]. Beads were then
washed, pelleted, boiled in SDS sample buffer, and subjected to immunoblot analysis. As shown
in Figure 3.16 A) As can be seen in the results, the pre-treated cells with H2O2 induced binding of
∆40APE-1wt to nuclear transcription factors such as Nrf-2 and STAT3. While, the binding is
significantly reduced in post-treatment with H2O2, suggesting that the oxidized APE/Ref-1 protein
impaired its binding capacity to nuclear transcription factors.
We further conducted the same GST pull down analysis experiment using GST-∆40APE-1C138A
mutant protein. The GST-∆40APE-1C138A mutant protein expressed and purified as described
before 2.1.1. Purified GST-∆40APE-1C138A mutant protein was oxidized by H2O2 (200 µM)/Fe2+
(5 µM and 10 µM) overnight, followed by washing and centration spin to remove H2O2/Fe2+. 100
µg of the protein was immobilized on glutathione beads and incubated with nuclear extraction of
melanoma cells at room temperature overnight [67]. Beads were then washed, pelleted, boiled in
SDS sample buffer, and subjected to immunoblot analysis. The bands were scanned and analyzed
by Bio-Rad ChemiDoc XRS+ system and normalized to GST-∆40APE-1C138A levels. As shown in
the Figure 3.16 B) the mutated ∆40APE-1C138A protein significantly reduced binding of ∆40APE-
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1C138A to STAT3 compared to control, suggesting that the Cys138 is critical for the direct binding
of APE/Ref-1 with STAT3.
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Figure 3.16 A) Pull-down analysis results of the GST-∆40APE-1wt protein with nuclear
extraction of melanoma cells. The experiment was repeated at least three times and as
can be seen in the results, the pre-treated cells with H2O2 induced binding of ∆40APE1wt to Nrf-2 and STAT3. While, the binding is significantly reduced by oxidization of
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∆40APE-1wt with H2O2, which can be suggested that the redox status of APE/Ref-1
protein not only affects its dimerization but may also regulate its redox activity. B)
Shows the same experiment using mutated ∆40APE-1wt protein. As shown in the
results, after mutation of Cys138, the binding of ∆40APE-1C138A protein to the TFs such
as STAT3 has been significantly reduced in pre-treated cells with H2O2 compared to
∆40APE-1wt (results in A). This result may validate our hypothesis that the redox
activity of ∆40APE-1wt is affected by its dimerization.
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4 Discussion
Human cutaneous melanoma is among the most fatal and the most drug resistance of all
malignancies in the United States in which the incidence rate continues to increase, making this
disease a rising public health concern [2]. Invasive melanoma accounts for less than 2% of all skin
cancer cases, but the vast majority of skin cancer deaths [68]. Despite powerful immunotherapy
approaches for the treatment of cutaneous melanoma (CM), these inhibitors are mainly indicated
for patients with advanced melanoma, leaving the world-wide melanoma epidemic and the
incidence to rise [5, 69, 70]. APE/Ref-1, first recognized as a DNA endonuclease base excision
repair (BER) enzyme that is found to plays an essential role in cancer cells survival from oxidative
stress associated with radiation therapy and chemotherapy [71-73]. Abnormal expression of
APE/Ref-1 in many human malignancies, including melanoma, has spurred efforts in the
development of APE/Ref-1 novel redox inhibitors with redox regulation recognition mediated
signaling.
To date, the development of the most successful, clinically available APE/Ref-1 inhibitor,
APX3330 (NCT03375086), also known as E3330, has shown markedly decrease mediate
oxidative stress compared with melanocytes [8]. E3330 exhibited therapeutic effects on tumor
angiogenesis and growth with selective redox recognition without altering APE/Ref-1
endonuclease activity [74-77]. However, such inhibitory activity is mainly evident at higher
concentrations of 50 µM [78]. Studies have indicated the redox signaling pathways of APE/Ref-1
via reduction of oxidized cysteine residues at certain nuclear transcription factors (TFs), converting
them to a reduced state, resulting in the upregulation of tumor-promoting genes [8]. As such,
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blocking APE/Ref-1 signaling pathway may inhibit broader downstream regulatory pathways,
suggesting being more effective and efficient in melanoma suppression. To date, a limited number
of compounds are proposed to exhibit APE/Ref-1 inhibitory pathways such as CRT0044876 (AP
endonuclease site inhibitory; Koll et al., 2008; Madhusudan et al., 2005), and PNRI-299 (AP-1
transcription activation with little effect on NF-kB; Nguyen et al., 2003). However, biological
activity analyses of such novel inhibitors demonstrated deficient cytotoxicity in our tested
melanoma cell lines even at high concentrations of 100 to 400 µM. To be best of our knowledge,
limited successes have been reported in the development of novel APE/Ref-1 inhibitors using
structure-based approach. An important component of our study is to design, and screen small
molecular inhibitors based on the APE/Ref-1 structure and their binding characteristics.
In our previous studies, the redox domain of APE/Ref-1 structure was selected for screening and
molecular modeling. First, virtual screening of molecules from ICN database with over 3 million
compounds was carried out using ICM software package developed by MolSoft L.L.C [36, 37].
The software incorporates ligand flexibility and ranks their binding using an energetic scoring
function, which allows identification of top-ranked candidates. We further conducted cell-based
bioactivity screening, and successfully developed our potent APE/Ref-1 inhibitor, R21; Biscinnamoyl-1,12-dodecamethylenediamine (N,N'-(dodecane-1,12-diyl)-bis(3-phenylacrylamide).
Despite the superior anti-proliferation and anti-angiogenesis activity of R21 against several human
malignancies, the compound had low water solubility, which we further improved the water
solubility

and

successfully

synthesized

R21-OH;

N-(12-cinnamamidododecyl)-3-(4-

hydroxyphenyl) acrylamide. The viability assay conducted on our promising APE/Ref-1 inhibitor,
R21-OH, evident its effective anti-melanoma activity at a concentration as low as 5 µM with
improved water solubility.
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To determine the binding activity of APE/Ref-1 with our promising inhibitor, R21-OH, and to
further develop more bioavailable and potent inhibitors, we conducted crystallization study using
purified truncated ∆40APE-1wt protein. Our successfully solved co-incubated structure failed to
identify any binding of our potent compound, R21-OH, with ∆40APE-1wt protein; however, we
did see the dimerization at cysteine 138 residue between two ∆40APE-1wt monomers. As detailed
previously in our studies [13], the redox regulation of APE/Ref-1 is greatly affected under
oxidative stress such as H2O2 or by cysteine replacement through site-directed mutagenesis. As
such, our dimer structure obtained by co-incubation with our potent compound, R21-OH, can lead
to a novel anti-tumor mechanism of APE/Ref-1. In support to our hypothesis, we then conducted
crystallization of ∆40APE-1wt under oxidative stress (200 µM H2O2 + 10 µM Fe2+). Our solved
structure form oxidized crystals also indicated the formation of a disulfide bond at cysteine 138
residue, which may greatly inhibit the redox regulation of APE/Ref-1.
We also conducted western blot experiment to determine whether our potent compound, R21-OH,
facilitates dimerization of APE/Ref-1 using 10 mM TCEP (reducing reagent) as the negative
control. As shown in this study, we found that monomer is the predominant form of ∆40APE-1wt
under reducing condition, and when exposed to 10mM TCEP (reducing reagent), a conversion
from dimer to monomer is evident. Our results from R21-OH incubation with the reduced
∆40APE-1wt also evident that our potent compound, R21-OH, facilitates dimerization of ∆40APE1wt in a dose-dependent manner. Furthermore, we have identified the critical role of Cys138 in
redox regulation of APE/Ref-1, as the predominant monomer form of ∆40APE-1C138A mutant
protein was observed under oxidative stress and in the presence of R21-OH. The effect of cysteine
138 in APE/Ref-1 dimerization may help us explain the distinct redox regulation activity of
APE/Ref-1, which may also provide new insight into the development of further novel inhibitors.
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As explained in details earlier, studies on human melanoma cell lines have demonstrated the major
role of APE/Ref-1 as an adaptive response to redox disequilibrium, which can promote cancer
progression, and emerge drug resistance via maintaining its redox regulation and DNA repair
activities [38, 79, 80]. It has been well established that the transcriptional activities of APE/Ref-1
are substantially affected by elevated levels of oxidative agents such as H2O2 and •OH (ROS
species) [81]. Induced levels of ROS, can generate oxidative DNA damage, which correlates with
endonuclease and redox activity of APE/Ref-1 [81, 82]. Redox sensitive signaling of APE/Ref-1
can modulate gene expression of many transcription factors, including Nrf2 and STAT3 [80, 82,
83], and regulate intracellular redox state by inhibition of ROS production. Early pancreatic studies
have demonstrated that the transcriptional activates of STAT3, is directly regulated by redox
regulation of APE/Ref-1 [80], which can contribute to melanoma survival and proliferation [84,
85]. As such, many efforts have been implemented to target STAT3 signaling as a therapeutic
strategy for melanoma treatment. Additionally, the antioxidant defense mechanism of Nrf-2 via
mediate signaling on a set of antioxidant proteins via binding to antioxidant response elements
(ARE) is well understood [39]. In our preliminary studies, we revealed the effect of Nrf-2 on
antioxidant downstream target gene NQO1 expression via cells sensitize to H2O2 toxicity
depletion, which significantly reduced APE/Ref-1 expression [12] to regulate and maintain redox
homeostasis and cell survival [22]. Our pull-down analysis obtained from nuclear extraction of
melanoma cells indicate a significant reduction of ∆40APE-1wt binding to TFs such as Nrf-2 and
STAT3 after H2O2 treatment. We also found that mutation of cysteine 138 (∆40APE-1C138A) may
completely knock down APE/Ref-1 binding to Nrf-2, and remarkedly reduced binding to STAT3
in oxidative stress. Our results are suggesting that the redox status of APE/Ref-1 protein not only
affects its dimerization but may also regulate its binding activity to TFs. To date, limited successes

54

have been reported in developing novel APE/Ref-1 inhibitors. The structural information collected
by our study is critical to guide further design and synthesis of inhibitors targeting APE/Ref-1 to
improve cancer treatment. The most potent inhibitor developed by our group using this structurebased approach showed promising anti-melanoma activities both in vitro and in vivo.
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5 Conclusion
Apurinic/apyrimidinic endonuclease (APE)/Redox Factor-1 (Ref-1) was first recognized as a DNA
endonuclease base excision repair (BER) enzyme [8] through cleavage of the phosphodiester bond
at either the 5’ or 3’ end of an apurinic or apyrimidinic site [86]. APE/Ref-1 also serves as an
essential redox regulation node of many nuclear transcription factors, such as Nrf-2, AP-1 dimers,
Myb, NF-κB, p53, and HIF [8] in a redox-dependent manner, resulting in transcriptional activation
of genes associated with cancer proliferation and progression. Many studies have proposed the
major role of Cys65, Cys93, and Cys99 in the redox function of APE/Ref-1 [87, 88]. However,
the structural studies of APE/Ref-1 show that these residues are not only buried in the core of the
protein and not accessible, but they are also not in proximity to one another to participate in the
formation of a disulfide bond [87, 88].
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Figure 5.1. Human APE-1 structure (PDB: 5CFG, green) includes seven Cys residues.
None of the cysteine residues is found forming disulfide bond within the molecule. A)
Highlighted location of Cys65, Cys99, Cys310, and Cys208 residues at ∆40APE-1wt.
B) Highlighted location of Cys65, Cys93, Cys99, Cys138, Cys208, and Cys296 of
∆40APE-1wt. C) Highlighted location of C138 of ∆40APE-1wt.

We also conducted a structural strategy to determine the binding profile of ∆40APE-1wt protein
with our potent inhibitor, R21-OH, and to further develop APE/Ref-1 inhibitors for human
melanoma therapy. Our structure study revealed that R21-OH facilitates the dimerization of
APE/Ref-1 in vitro, which may be an innovative mechanism contributing to its anti-melanoma
activity.
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Additionally, we studied the effects of oxidation on APE/Ref-1 dimerization and redox regulation
of nuclear transcription factors in human melanoma cell lines. We demonstrated that the redox
environment not only affects the dimerization of APE/Ref-1 protein, but also regulates the
interactions of APE/Ref-1 with nuclear transcription factors such as Nrf-2 and STAT3. For the
first time, we demonstrated the structural transformation of the APE/Ref-1 protein under distinct
redox conditions, which may contribute to its redox regulation of nuclear transcription factors.
These novel observations pave the way for future drug development and optimization for
melanoma therapy.

O2
H2

∆40APE-1wt

SH

Oxidize

∆40APE-1wt S

S

∆40APE-1wt

Reduce
B

A
∆40APE-1wt SH

∆40APE-1wt S

Nrf-2

S

∆40APE-1wt

Nrf-2
Figure 5.2 Possible mechanism of APE/Ref-1 redox regulation of nuclear transcription
factors. As shown in the A) pathway, the reduced ∆40APE-1wt binds with nuclear
transcription factors such as Nrf-2 by direct interaction through the active cysteine
residue and subsequently activates the transcription of downstream target genes.
However, under oxidative condition such as hydrogen peroxide (H2O2) exposure (as
shown in B), the redox regulation of ∆40APE-1wt will form a dimer structure linked
with Cys138-disulfide bond. Such dimer will no longer be able to bind and activate
nuclear transcription factors, which may lead to inactivation of APE/Ref-1-mediated
signaling.
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